ReviewChemical & biomedical imaging2026
Spatiotemporal and Digital Electrochemiluminescence Imaging for Intelligent Quantitative Biosensing.
Review in Chemical & biomedical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanistic insights into electrochemiluminescence: fueling advances in bioanalysis and imaging.Chemical science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Electrochemiluminescence (ECL) imaging has progressed from a sensitive-intensity-based detection method to a powerful analytical platform capable of resolving biological and chemical heterogeneity at the single-entity level. This review maps the evolution of ECL imaging along three major axes: (i) spatiotemporal resolution, enabled by advanced luminophores, confined and built-in coreactant pathways, nanozyme catalysis, and 3D emissive-layer control; (ii) digitalization, in which analog luminescence is converted into discrete, statistically robust events for ultrasensitive quantification; and (iii) intelligent analysis, where artificial intelligence enhances denoising, emitter localization, dynamic tracking, multiplexed decoding, and kinetic inference. Mechanistic innovationssuch as nanoscale confinement, intramolecular coreactant design, in situ conversion of endogenous metabolites, and asymmetric nanostructuresprovide brighter, more localized, and biocompatible emission sources. Parallel advances in materials (metal nanoclusters, quantum dots, perovskites, AIE luminogens, Janus particles), imaging platforms (SECL/PECL modes, super-resolution strategies, microfluidics, smartphone/Raspberry-Pi devices, and large-scale bipolar-electrode arrays), and digital/AI pipelines collectively enable the high-fidelity capture of dynamic processes from single molecules to complex 3D spheroids. Together, these developments establish a coherent spatiotemporal-digital-intelligent framework and position ECL imaging as a versatile, scalable, and excitation-free modality for next-generation biosensing, clinical diagnostics, drug screening, environmental monitoring, and functional material characterization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.